Blockade of interleukin-6 in murine sepsis revisited: Is there an indication for a new therapy in human patients?

Critical Care Medicine

Volumn 39, Issue 6, 2011, Pages 1582-1583

  Kurdowska, Anna ^a   Krupa, Agnieszka ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

cytokines; IL 6; inflammation; sepsis; therapy

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

EDITORIAL; HEMORRHAGIC SHOCK; HUMAN; INFLAMMATION; LIGATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNCTURE; SEPSIS; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

EID: 79957652043     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318215c0ba     Document Type: Editorial

References (14)

1. Hattori Y, Takano K, Teramae H, et al: Insights into sepsis therapeutic design based on the apoptotic death pathway. J Pharmacol Sci 2010; 114:354-365.
2. Wheeler DS: Death to sepsis: Targeting apoptosis pathways in sepsis. Crit Care 2009; 13:1-3.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310. (Pubitemid 32641789)
4. Dombrovskiy VY, Martin AA, Sunderram J, et al: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244-1250. (Pubitemid 46642649)
5. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554. (Pubitemid 36437931)
6. De Jong HK, Van Der Poll T, Wiersinga WJ: The systemic pro-inflammatory response in sepsis. J Innate Immun 2010; 2:422-430.
7. Kishimoto T: IL-6: From its discovery to clinical applications. Int Immunol 2010; 5:347-352.
8. Barkhausen T, Tschernig T, Rosenstiel P, et al: Selective blockade of interleukin-6 transsignaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 2011; 39:1407-1413.
9. Vyas D, Javadi P, Dipasco PJ, et al: Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol 2005; 289:1048-1053.
10. Riedemann NC, Neff TA, Guo RF, et al: Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003; 170:503-507. (Pubitemid 36026177)
11. Mees ST, Toellner S, Marx K, et al: Inhibition of interleukin-6- transsignaling via gp130-Fc in hemorrhagic shock and sepsis. J Surg Res 2009; 157:235-242.
12. Wheeler DS, Zingarelli B, Wheeler WJ, et al: Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov 2009; 3:96-112.
13. Anas AA, Wiersinga WJ, De Vos AF, et al: Recent insights into the pathogenesis of bacterial sepsis. The Netherlands J Med 2010; 68:147-152.
14. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205 (Pubitemid 35222596)